Filter by: patients
Home > Community Treatment Reports and Side Effects > MS Phase 3 Study Teriflunomide (HMR1726) TOWER Treatment Report
What is MS Phase 3 Study Teriflunomide (HMR1726) TOWER?

NCT00751881 is a multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of the drug teriflunomide in patients with relapsing multiple Sclerosis. Other study IDs include: TOWER, EFC10531, EudraCT: 2007-004452-36.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 1 1 Efficacy_cant_tell

See all 2 patients currently using MS Phase 3 Study Teriflunomide (HMR1726) TOWER

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 1
None
 0

Reported Schedules

  1 other daily 2 daily
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Duration See details about how long patients take this treatment ▼

Currently Using MS Phase 3 Study Teriflunomide (HMR1726) TOWER

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of MS Phase 3 Study Teriflunomide (HMR1726) TOWER

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of MS Phase 3 Study Teriflunomide (HMR1726) TOWER

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of MS Phase 3 Study Teriflunomide (HMR1726) TOWER

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 26, 2012.